Baseline Assessment

Before jumping into the activity content, reflect on your current knowledge of pharmacotherapies used to optimize joint health and surgical outcomes in those who are overweight or obese.
Tiffany N. Lowe Clayton, DO, FOMA, DABOM, MHPE

Vice-Chair, Dept. Family Medicine
Campbell University School of Osteopathic Medicine
Bariatrician WakeMed Bariatric Surgery
and Medical Weight Loss
Cary, North Carolina

Tiffany N. Lowe Clayton, (a.k.a Dr. TLC), is an assistant professor and director of clinical education at Campbell University School of Osteopathic Medicine in Lillington, North Carolina. She is also an obesity medicine specialist at WakeMed Bariatric Surgery and Medical Weight Loss, with practices in both Cary and Fuquay-Varina, North Carolina. Additionally, she is the Founder and CEO of the Institute of Transformational Health and Wellness, Inc. in Wendell, North Carolina. She earned her medical degree in 2000 from Rowan University School of Osteopathic Medicine in Stratford, New Jersey, where she also completed an internship and residency in family medicine in 2003. A consummate teacher at heart, Dr. TLC is the author of the best-selling book, “A Woman’s Guide to De-Stress for Success: 10 Essential Tips to Conquer Stress and Live At Your Best.” In her personal life, Dr. TLC is a devoted wife, mother, and “Glamma.” She enjoys spending time with her family as well as traveling, singing and recreational boxing.

Carisa Tripi, DO

Medical Surgical Director
San Luis Valley Health - Alamosa, Colorado
Team Physician - Adams State University

Dr. Tripi is a practicing Board Certified Orthopedic Surgeon. After completing her Sports Medicine Fellowship through Henry Ford Hospital in Detroit, MI, she moved to southern Colorado where she has been actively practicing for 13 years. She became a Diplomate of the ABOM in 2020 after identifying a paucity in treatment options for her patients experiencing the musculoskeletal effects of obesity. She is passionate about providing Evidence Based education to her patients both from an orthopedic and obesity management standpoint.  

Neil Skolnik, MD

Professor of Family and Community Medicine 
Sidney Kimmel Medical College 
Thomas Jefferson University 
Associate Director 
Family Medicine Residency Program
Jefferson Health - Abington

Dr. Neil Skolnik, MD, is a Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Associate Director of the Family Medicine Residency Program at Jefferson Health - Abington. Dr. Skolnik has written and edited 6 books and has published more than 500 articles, columns, poems, essays and webinars in both the medical and lay literature including publications in JAMA, JAMA Internal Medicine, Annals of Internal Medicine, Circulation, Medscape, Philadelphia Inquirer and USA Today. He has served on the Expert Panel Report 4 (EPR-4) Working Group, National Asthma Education and Prevention Program Coordinating Committee, National Heart Lung Blood Institute (NHLBI) – the committee that developed the 2020 NIH Asthma Guidelines. He hosts and produces “Diabetes Core Update,” the American Diabetes Association’s official monthly podcast that reviews the most important new articles to come out in the diabetes literature every month, as well as “Diabetes Day by Day”, the ADA’s podcast for people with diabetes. He tries to make sure that each day he spends at least 30 minutes playing the guitar and, to the chagrin of his wife, singing.

1.
UNDERSTAND the clinical benefits of GLP-1 receptor agonists for obesity and its related comorbidities.
2.
IDENTIFY and MANAGE the adverse event profiles associated with GLP-1 receptor agonists using evidence-based strategies.
3.
DEVELOP patient-centered strategies to educate patients about the benefits, risks, and expectations of GLP-1 receptor agonist therapy.
4.
IMPLEMENT follow-up protocols to monitor patient progress, manage side effects, and improve adherence to GLP-1 receptor agonist therapy.
5.
DESCRIBE how GLP-1 receptor agonists align with orthopedic-specific care priorities, such as joint health.
6.
INDIVIDUALIZE counseling and management approaches for GLP-1 receptor agonist therapy to address orthopedic-specific patient needs, such as  joint-related comorbidities.